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This report evaluates the scientiﬁc literature on caffeine with respect to potential central nervous system
(CNS) effects, speciﬁcally effects on sleep, anxiety, and aggression/risk-taking. Caffeine has been the
subject of more scientiﬁc safety studies than any other food ingredient. It is important, therefore, to
evaluate new studies in the context of this large existing body of knowledge. The safety of caffeine can
best be described in a narrative form, and is not usefully expressed in terms of a “bright line” numerical
value like an “acceptable daily intake” (ADI). Caffeine intake has been associated with a range of
reversible physiological effects, in a few studies at levels of less than 100 mg in sensitive individuals. It is
also clear that many people can tolerate much greater levels e perhaps up to 600e800 mg/day or more
e without experiencing such effects. The reasons for this type of variability in response are described in
this report. Based on all the available evidence, there is no reason to believe that experiencing such
effects from caffeine intake has any signiﬁcant or lasting effect on health. The point at which caffeine
intake may cause harm to the CNS is not readily identiﬁable, in part because data on the effects of daily
intakes greater than 600 mg is limited. Effects of caffeine on risk-taking and aggressive behavior in young
people have received considerable publicity, yet are the most difﬁcult to study because of ethical con-
cerns and limitations in the ability to design appropriate studies. At present, the weight of available
evidence does not support these concerns, yet this should not preclude ongoing careful monitoring of the
scientiﬁc literature.
© 2015 Ramboll Environ US Corporation. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Caffeine (1,3,7-trimethylxanthine) is a central nervous system
(CNS) stimulant alkaloid that is found in various plants such as
coffee and cocoa beans, tea leaves, guarana berries, and the kola
nut. It has been described as the most frequently ingested phar-
macologically active food substance in the world (IOM, 2014). As
noted in the proceedings of Institute of Medicine (2014) workshop
on caffeine, “years of scientiﬁc research have shown that moderate
consumption by healthy adults of products containing naturally
occurring caffeine is not associated with adverse health effects.”
And a similar conclusion was reached by the European Food Safety
Authority (EFSA, 2015).
This report evaluates the scientiﬁc literature on caffeine relative
to possible CNS effects, especially effects on: sleep/sleep distur-
bance; anxiety; and aggression/risk-taking behavior, particularly atull).
Published by Elsevier Inc. This is alevels of intake higher than the “moderate” levels identiﬁed by IOM
and EFSA. A fourth area of investigation relates to possible caffeine
tolerance, and withdrawal.
While there is substantial scientiﬁc evidence of beneﬁcial effects
of caffeine, including evidence that chronic caffeine consumption
may have neuroprotective effects and is associated with better
cognitive performance later in life, e.g., inverse correlations with
the risk of developing Parkinson's and possibly Alzheimer's disease
(Costa et al., 2010; Prediger, 2010; Santos et al., 2010; Yang et al.,
2010), these effects are not addressed in this report.2. Approach and methodology
We identiﬁed relevant, high-quality studies in humans from
authoritative secondary sources e.g., European Food Safety Au-
thority (EFSA) 2015; Nawrot et al., 2003; Institute of Medicine
(IOM) 2001; Oak Ridge National Laboratory (ORNL) 2011, as well
as through an updated literature search for more recent relevant
studies using the PubMed bibliographic database.n open access article under the CC BY-NC-ND license (http://creativecommons.org/
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2014 through March, 2015 and included the following terms:
(((caffeine[Title/Abstract] OR coffee[Title/Abstract])) OR
(caffeine[MeSH Terms]) AND ((adult* OR adolescent* OR child* OR
female ORmale ORwomanORwomen ORman ORmen) NOT (baby
OR babies OR infant*)[Title/Abstract])) OR ((adult* OR adolescent*
OR child* OR female OR male) NOT (baby OR babies OR infant*)
[MeSH Terms]) AND ((“adverse effect*” OR “health effect*” OR
*toxic* OR behaviour OR behavior OR attention OR psych* OR sleep
OR anxiety OR aggression OR “risk taking” [MeSH Terms])) OR
(adverse effect*” OR “health effect*” OR *toxic* OR behaviour OR
behavior OR attention OR psych* OR sleep OR anxiety OR aggres-
sion OR “risk taker*” OR “risk taking” [Title/Abstract])
((((adult*[Title/Abstract] OR adolescent*[Title/Abstract] OR
child*[Title/Abstract] OR female[Title/Abstract] OR male[Title/Ab-
stract] OR woman[Title/Abstract] OR women[Title/Abstract] OR
man[Title/Abstract] OR men) NOT (baby[Title/Abstract] OR babies
[Title/Abstract] OR infant*))[Title/Abstract])) AND (adverse
effect*“[Title/Abstract] OR “health effect*”[Title/Abstract] OR
*toxic*[Title/Abstract] OR behaviour[Title/Abstract] OR behavior
[Title/Abstract] OR attention[Title/Abstract] OR psych*[Title/Ab-
stract] OR sleep[Title/Abstract] OR anxiety[Title/Abstract] OR
aggression[Title/Abstract] OR “risk taker*”[Title/Abstract] OR “risk
taking”[Title/Abstract]).
Studies for evaluation were identiﬁed on the basis of their
citation by authoritative bodies, appropriate design, adequate study
sample size, and appropriate control of potential confounders.
Because of the inability of observational studies to identify causa-
tion, particular emphasis was placed on experimental or inter-
ventional studies in which exposures could be well controlled, and
responses to those exposures carefully measured or monitored.
High-quality observational studies were also considered to assist in
evaluation of potential effects of prolonged exposure, since exper-
imental studies were all of relatively short duration.
Following the identiﬁcation of potentially relevant studies, we
reviewed them in more detail to determine which studies exam-
ined the potential relationship between caffeine dose and the
relevant CNS effects. Following the identiﬁcation of these studies,
we extracted data to assess how the occurrence of these CNS effects
varies in incidence/severity with caffeine dose and duration of
exposure among the subpopulations of interest. Almost 200 studies
were included in the database of pertinent studies (see
Supplemental Materials).
2.1. Glossary
Adolescent: adolescence is generally thought to be the period
from puberty to adulthood. Although there is a range for the onset
of puberty, we have used the range of 11e13 to 19 as a “working
range.”
Anxiety: an emotion characterized by feelings of tension and
worried thoughts, generally assessed (in the studies evaluated
here) by standardized questionnaire (e.g., proﬁle of mood states e
POMS), or using a visual analog scale.
Dependence: A state in which an organism functions normally
only in the presence of a drug, commonly manifest in the context of
withdrawal when physiological reactions occur that can range from
mild and short-term (e.g., caffeine withdrawal headache) to life-
threatening (alcoholic delirium tremens).
Habitual: Daily (or near-daily) consumption.
Naïve: Never or rare consumption.
Sleep disturbance: Signiﬁcant change in normal sleep pattern/
sleep parameters, particularly increased sleep latency (delay in
falling asleep after retiring), decreased sleep duration, increased
nocturnal awakening, or alterations in sleep stages.2.2. Background
In a recent survey of caffeine consumption in the US population,
results showed that 84% of the US population consumes at least one
caffeinated beverage per day, and the mean daily caffeine intake
from all beverages was 165 ± 1 mg for all ages combined (Mitchell
et al., 2014). Similar levels of intake have been reported for adults
by Fulgoni et al. (2015), based on data from the National Health and
Nutrition Examination Survey (NHANES) for 2001 through 2010. At
such levels of intake, caffeine can produce a number of physiolog-
ical effects related to the central nervous system (CNS). Caffeine
“bioactivity” has been known for well over a century and is widely
(if not completely) understood by consumers. In these respects,
caffeine is unique among common constituents of foods.
The physiological activities of caffeine are known to vary among
individuals. An important contributor to variability relates to the
well-known fact that individuals develop tolerance to certain
physiological effects of caffeine. Thus, with repeated and regular
intake, the level of intake needed to induce caffeine's physiological
effects increases. Individuals who are not habitual users do not
develop tolerance, and thus, when they do ingest caffeine, they
typically experience the compound's physiological effects at lower
levels of intake than do habitual users.
In addition, several genetic polymorphisms have been identiﬁed
that affect the metabolism of caffeine and its interaction with re-
ceptors that mediate its CNS effects.
For all of these reasons, it is not possible to identify a single level
of intake for the general population that would otherwise induce
caffeine's physiological CNS effects. Moreover, the ordinary physi-
ological CNS effects of caffeine are not known to cause any harm to
health. The physiological CNS effects that result are transient and
reversible and have no known long-term health consequences e
they are not adverse (in fact, some clearly have beneﬁts, such as
increased alertness and mental acuity).
Also, some people can consume greater levels than others. For
example, in the recent study of US caffeine consumption (Mitchell
et al., 2014), the 90th percentile consumption level among adults
aged 50e64 was 467.4 mg/day. To establish so-called “safe” levels
of intake based on non-adverse physiological effects of the most
sensitive individuals e even when those effects are not in the true
sense adverse e would disproportionately deprive the very large
numbers of people who can consume higher levels of caffeine
without a corresponding increase in public health beneﬁt. Such an
approach would be analogous to setting limits onmilk intake based
on tolerable levels of lactose intake by lactose-intolerant
individuals.
Truly unsafe levels of intake, as noted previously, will likely not
occur until very high levels, e.g., >100 mg/kg bw/day (more than
6000 mg/person/day; Boyd et al., 1965) e associated with bona ﬁde
adverse effects resulting in acute caffeine toxicity e are achieved.
Individuals consuming caffeine at varying levels of intake may
experience non-adverse physiological CNS effects that are simul-
taneously transient and reversible, and most may adjust intakes if
they perceive those effects as undesirable, i.e., they will self-titrate
(Soroko et al., 1996; Retey et al., 2007). Even if they do not adjust
intake, those physiological CNS effects will not result in harm to
their health. As a result, a single “bright line” between safe and
unsafe intakes (as in a traditional “acceptable daily intake”e ADI) is
unnecessary to avoid adverse health effects.
2.3. Deﬁnition of an adverse health effect
When evaluating the effects of caffeine consumption, it is
important to differentiate between a physiological CNS effect and
an adverse effect. Caffeine can cause subtle, reversible physiological
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clearly not adverse. Indeed, many individuals appreciate this
beneﬁcial effect of caffeine, which can be demonstrated experi-
mentally at dose levels at or below 100 mg. Of course, exaggeration
of this effect due to excessive intake can interfere with normal
sleep, or produce other undesirable effects, but which are not
necessarily adverse from a health outcome perspective.
Adverse effects have been deﬁned as follows:
“the causation, promotion, facilitation and/or exacerbation of a
structural and/or functional abnormality, with the implication
that the abnormality produced has the potential of lowering the
quality of life, contributing to a disabling illness, or leading to a
premature death” (Sherwin, 1983)
and:
“Adverse effects are considered to be functional impairments or
pathological lesions that may affect the performance of the
whole organism or that reduce an organism's ability to cope
with an additional challenge. One of the major problems
encountered with this concept is the reporting of ‘observed ef-
fect levels’ as contrasted to ‘observed adverse effect levels.’ The
terms ‘adverse’ and ‘not adverse’ are at times satisfactorily
deﬁned, but because more subtle responses continue to be
identiﬁed due to increasingly sophisticated testing protocols,
scientiﬁc judgment is needed regarding the exact deﬁnition of
adversity” (USEPA, 1994).
Effects that are transient, reversible, and do not have long-term
detrimental health consequences should not be considered
adverse.
It is important to note that this report does not address “Adverse
Event Reports” (AERs) associated with consumption of caffeine-
containing products. The FDA's Adverse Event Reporting System
(FAERS) is a database containing information on adverse event and
medication error reports submitted to FDA. Inmedical terminology,
an adverse event arises in the context of clinical trials of pharma-
ceuticals, and is used to refer to any occurrence during a clinical
trial that would be considered adverse whether or not it has any-
thing to do with the treatment being studied. For example, if
someone in such a trial was shot during a bank robbery, or hit by an
out-of-control truck, that would be classiﬁed as an adverse event.
AERs may also result from emergency room visits where the
medical staff collects all sorts of information that may have some
bearing on the incident, though it is generally not possible to
determine cause-and-effect relationships. More speciﬁcally, it is
not possible to determine whether an adverse event report has any
causal relationship to a particular exposure (such as consumption
of a caffeinated beverage).2.4. Possible variability in responses to caffeine
There are a variety of factors that may inﬂuence an individual's
response to caffeine. Drawing broad conclusions about the effects
of various intake levels of caffeine for the general population is thus
challenging. An individual's response may be inﬂuenced by phar-
macokinetic factors that affect how rapidly caffeine is absorbed,
distributed, metabolized and eliminated (ADME) after being
ingested, or by pharmacodynamics factors that inﬂuence the
interaction between caffeine and its site(s) of action and the effects
of that interaction on the body. Some of this variability results from
genetic polymorphisms e naturally occurring mutations in genes
involved in the metabolism of caffeine (particularly differences in
activity of cytochrome P450 1A2 which plays a major role incaffeine metabolism) or in adenosine receptors. Adenosine re-
ceptors are a class of purinergic G protein-coupled cell membrane
receptors with adenosine as endogenous ligand that are found
throughout the body, including the central nervous system
(Fredholm et al., 2001). Caffeine is a competitive antagonist of
adenosine at the A1 and A2A receptors (ADORA1 and ADORA2A),
and this antagonistic effect is believed to be responsible for many of
the physiological effects of caffeine (Nehlig 2007; Baraldi et al.,
2008). As discussed below, carriers of certain genetic poly-
morphisms of CYP1A2 and ADORA2A show differential effects of
caffeine exposure, though no differential effects have been reported
to date for ADORA1 polymorphisms (Rogers et al., 2010; Thorn
et al., 2012).2.5. ADME differences
Differences in ADME (including delayed gastric emptying which
can delay absorption), and metabolism (particularly differences in
activity of cytochrome P450 1A2 (CYP1A2)), lead to differences in
plasma caffeine levels and time course from the same dose
(Arnaud, 1993). For example, Birkett and Miners (1991) reported an
8-fold range in steady-state plasma caffeine concentration in six
adult volunteers given 150 mg caffeine every 8 h for 6 days.
The vast majority of ingested caffeine is metabolized, largely in
the liver, prior to excretion. The metabolic pathways are relatively
complex (Arnaud, 1993, 2011; see Fig. 1). At least 16 metabolites at
levels of 0.1% or more of administered caffeine dose may be found
in the urine of humans. In humans, the principal initial step is 3-
demethylation of caffeine (1,3,7-trimethylxanthine) to para-
xanthine (1,7-dimethylxanthine); 72e80% of ingested caffeine fol-
lows this route, and paraxanthine plasma levels exceed those of
caffeine within 8e10 h of ingestion (Bonati et al., 1982; Tang-Liu
et al., 1983). 3-Demethylation in humans appears to be catalyzed
speciﬁcally by cytochrome P450 1A2 (CYP1A2) (Butler et al., 1989).
There is substantial inter-individual variability of CYP1A2 ac-
tivity that inﬂuences the disposition of a substrate such as caffeine
and these variations may be due to factors such as gender, race,
genetic polymorphisms, exposure to enzyme inducers, age, exer-
cise, and pregnancy (Dorne et al., 2001; Vistisen et al., 1990). In
particular, at least 6 different polymorphic forms of CYP1A2
(CYP1A2*1A, CYP1A2*1D, CYP1A2*1F, CYP1A2*1L, CYP1A2*1V and
CYP1A2*1W) have been reported (Arnaud, 2011). Four other CYP
isoforms (CYP1A1, CYP2E1, CYP3A, and CYP2D6-Met) also have
minor roles in the metabolism of caffeine (Arnaud, 2011).
Caffeine half-lives of 2.5e4.5 h were measured in humans at
dose levels of 4 mg/kg body weight (bw) (Arnaud,1993). The ADME
proﬁle appears to be age-dependent in rats but not so in humans
(Feely et al., 1987; Latini et al., 1980; Blanchard and Sawers, 1983),
except in the very young; half-lives of 50e103, 14.4, and 2.6 h have
been observed in premature/newborn, 3e5 month and 5e6 month
infants, respectively (Gorodischer and Karplus, 1982; Parsons and
Neims, 1981; Aldridge et al., 1979; Paire et al., 1988; Pearlman
et al., 1989). Thus, caffeine clearance reaches or exceeds adult
levels by 5e6 months of age (Aranda et al., 1979; von Borstel, 1983).
Longer half-lives have been observed in breast-fed than in
formula-fed infants (Le Guennec and Billon,1987), and inwomen in
the last trimester of pregnancy compared with controls (Knutti
et al., 1981, 1982). This effect contributes to the recommendation
to limit caffeine intake during pregnancy.
Caffeine half-lives have also been found to increase up to
50e160 h in humans with severe liver diseases (Statland et al.,
1976; Statland and Demas, 1980; Desmond et al., 1980; Scott
et al., 1988).
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The other major source of variability in response to caffeine is
differences in the receptors in the brain involved in expression of
caffeine's physiological effects related to the central nervous sys-
tem (Yang et al., 2010).
In producing its physiological effects, the main receptor targets
for caffeine action on the CNS are adenosine A1 and A2A receptors
(ADORA1 and ADORA2A), where it acts competitively to adenosine.
Adenosine acts as an inhibitory neurotransmitter via A1 receptors,
which are located on both inhibitory and excitatory neurons
throughout the CNS. A1 receptors mediate the release of other
neurotransmitters, such as glutamate, acetylcholine, and dopa-
mine. Stimulatory effects of caffeine are thought to be due to the
reversal of the tonic inhibition of dopamine. Adenosine has inhib-
itory properties on A2A receptors, which are located mainly in the
striatum, together with dopamine D2 receptors. Adenosine's action
inhibits D2 transmission. These inhibitions are antagonized by
caffeine, which is thought to be responsible for its stimulatory ef-
fects on the psychomotor system (as reviewed in Yang et al., 2010).
Several single nucleotide polymorphisms (SNPs) in the ADORA2A
gene (though not in the ADORA1 gene) have been associated with
variations in sensitivity to caffeine's physiological CNS effects
(Alsene et al., 2003; Childs et al., 2008; Rogers et al. 2010; Yang
et al., 2010; Thorn et al., 2012).
Another gene polymorphism that seems to affect caffeine
sensitivity is in the gene for adenosine deaminase, an enzyme
responsible for the clearance of extracellular adenosine (Mazzotti
et al., 2011). These authors found that individuals carrying the A
allele (ADA G22A; rs73598374) who consumed caffeine in the day
prior to polysomnography demonstrated higher sleep efﬁciency
and REM sleep percentage compared to non-carriers of that allele,
after adjustment for potential confounders. No effect was observed
in the absence of caffeine.
2.7. Age considerations
Concerns have been raised in some fora that children may be
more sensitive than adults to the effects of caffeine and that,
therefore, children's exposure to caffeine should be restricted.
However, other than young infants, whose metabolic abilities may
not be completely developed until they are about six months old,
there is no evidence that children are inherently any more sensitive
than adults when their body weight is taken into consideration.
3. Results
3.1. Overview of literature
Numerous studies in humans were identiﬁed as potentially
relevant. These included 122 experimental studies (mostly ran-
domized controlled trials) and 41 observational epidemiology
studies. Of these, 96 experimental, and 24 observational studies
were included in the ﬁnal analysis because they included infor-
mation on caffeine dose and examined the relevant CNS effects.
This included 7 experimental and 12 observational studies in
children. In some of the observational studies, dose information
related to caffeine intake was presented in values that were too
imprecise to draw ﬁrm conclusions about speciﬁc dose effects. For
example, some studies only report group means by endpoint, or
present a very general intake level (e.g., 1 drink per day).
All of the studies identiﬁed and retrieved are summarized in the
associated Excel spreadsheet database. These spreadsheet entries
go into greater detail on all aspects of the studies and should be
consulted for speciﬁc information.Thewealth of studies on these aspects of caffeine's CNS effects is
rare for a food ingredient, and permits a thorough evaluation of
caffeine's possible CNS effects. It must be recognized, however that
even this extensive database has limitations. While the extensive
human experimental studies are of great beneﬁt, most involve only
a single or a few repeated administrations, thus limiting to some
extent our understanding of the effects of long-term caffeine con-
sumption, though many of these limitations are balanced by the
substantial number of observational epidemiology studies that
address long-term consumption.
One additional limitation is that relatively few studies examined
high doses (i.e., >600 mg/day) never mind very high doses (i.e.,
>1200 mg/day), making it difﬁcult to identify clear adverse effect
levels. The latter provides the scientiﬁc basis to establish a mini-
mum threshold of 600 mg/day as an appropriate safety default
absent data supporting higher levels.
In the following sections, each of the primary CNS endpoints of
interest, sleep, anxiety, and aggression/risk-taking are addressed.
These three primary sections are followed by a brief discussion of
the phenomena of tolerance and withdrawal.
3.2. Sleep/sleep disturbance
The advent of the 24-h society has contributed to prevalence of
sleep disturbance among the population (Rajaratnam and Arendt
2001). While extreme forms of sleep disturbance may rise to the
level of a clinical disease, and could represent an “adverse health
effect,” the effects of caffeine on sleep are typically mild e a slight
delay in falling asleep and slightly decreased sleep duration. They
are also entirely reversible when caffeine intake is reduced, and are
such a well-known effect of caffeine that individuals typically
modify their caffeine consumption if they ﬁnd that it interferes
with sleep (Soroko et al., 1996; Retey et al., 2007). Also, as discussed
above, individuals vary in their sensitivity to these effects of
caffeine.
A total of 54 studies (42 experimental, 12 observational)
examined the potential relationship between caffeine intake and
various sleep endpoints. These endpoints were studied primarily
among adult participants, with 8 observational studies of children.
Few studies examined the effects of low levels of caffeine
(<100 mg) on sleep (1 experimental study and 1 observational
study). “Virtually no effect on sleep patterns” was observed among
18 young adult males (who normally drank 1e4 cups of coffee per
day) when they consumed instant coffee containing 1.1mg/kg body
weight (bw) caffeine 30 min before bedtime for 13 days (Karacan
et al., 1976). Interestingly, boys, but not girls, aged 10e12 years
who drank less than one energy drink or cola per day (caffeine dose
not otherwise identiﬁed) reported signiﬁcantly more sleeping
problems compared to children with no caffeine intake in the
observational study (Kristjansson et al., 2014), as described more
fully further below.
Doses as low as 100 mg within 2 h of bedtime can have subtle
effects on sleep parameters (Landolt et al., 1995a), with clearer,
dose-related effects reported at higher doses (ingestion of
300e400 mg caffeine increased sleep latency and decreased
amounts of slow-wave sleep and total sleep time). Some studies
suggest a lack of effect on sleep when given 6- or 16-h before sleep
(Snel, 1993; Bonnet and Arand, 1992; Pontifex et al., 2010), though
Landolt et al. (1995b) report a residual effect on some sleep pa-
rameters measured during the night (11 pme7 am) following
consumption of 200 mg caffeine at 7:10 am, compared to nights
when a placebo was consumed in the morning in 9 adult male
subjects. In six studies where caffeine intake was greater than
600 mg caffeine per day, the authors reported reductions in total
sleep time and sleep quality, and increased sleep latency and
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et al., 2005; Sanchez-Ortuno et al., 2005; Shilo et al., 2002;
Youngstedt et al., 2000). In one study where 12 young adult male
participants received 1200mg/day caffeine (divided in three doses)
for seven days, a variety of sleep parameters were negatively
affected including total sleep time, sleep latency, wake time, sleep
efﬁciency, number of wakes, and arousal index (Bonnet and Arand,
1992). Signiﬁcant effects observed on day one of the trial dis-
appeared formany of these parameters after the ﬁrst day of caffeine
intake (total sleep time, sleep latency, wake time, sleep efﬁciency,
number of wakes), suggesting evidence of acclimation and a
reversal of effects even while ingesting a high dose of caffeine for
several more days.
Among the 8 observational studies of children, the dose infor-
mation reported in ﬁve of the studies was too imprecise to draw
any ﬁrm conclusions about speciﬁc dose-effects (Calamaro et al.,
2009; Lee et al., 1999; Ludden and Wolfson, 2010; Mindell et al.,
2009; Pollak and Bright, 2003). Kristjansson et al. (2014), as
noted above, reported that in a study involving 11,267 children,
boys, but not girls, aged 10e12 years who drank less than one en-
ergy drink or cola per day (caffeine intake not otherwise identiﬁed)
reported signiﬁcantly more sleeping problems compared to chil-
dren with no caffeine intake. Both boys and girls who reported
drinking more than one cola or energy drink per day reported
signiﬁcantlymore sleeping problems than childrenwith no caffeine
intake. The results suggested a stronger relationship between en-
ergy drinks and sleeping problems than for cola drinks among boys,
though the cross-sectional design of the study precludes any
inference of causation. Also, sleeping problems were reported
signiﬁcantly more commonly by girls than by boys, though con-
sumption of energy drinks was twice as common among boys than
among girls, further limiting the conclusions that can be drawn
from this study. Orbeta et al. (2006) reported that in a study
involving 15,686 children in grades 6e10 e i.e., eleven to sixteen
years of age e those who drank 1 coffee or soda per day (caffeine
intake not otherwise identiﬁed) were signiﬁcantly more likely to
report difﬁculty sleeping compared to children with very low
intake (<1/week). Children with low intake (1/week) were not
signiﬁcantly more likely to report difﬁculty sleeping.
Santos et al. (2012) reported that in a study involving 885 in-
fants, maternal consumption of 300 mg/day caffeine during the
1st, 2nd, or 3rd trimester, during the whole pregnancy, or at 3
months postpartumwas not signiﬁcantly associated with >3 night-
time wakings per night among infants at 3 months of age.
Eleven experimental studies included testing of salivary caffeine
levels in participants to ensure compliance as well as to examine
the relationship between an objective measure of caffeine levels
that might otherwise differ among individuals due to differences in
caffeine metabolism in the liver, and potential sleep-related effects
(Carrier et al., 2007, 2009; Drapeau et al., 2006; Hale et al., 1995;
James, 1998; Lader et al., 1996; Landolt et al., 1995a, 1995b;
Paterson et al., 2007; Retey et al., 2007; Sicard et al., 1996). Previ-
ous studies have shown a close association between saliva and
plasma levels of caffeine (Landolt et al., 1995a). As salivary caffeine
is correlated with plasma caffeine in a ratio of 0.74 ± 0.08, circu-
lating caffeine can be estimated by salivary caffeine assays (Sicard
et al., 1996). Following intakes ranging from 100 to 600 mg,
caffeine intake was associated with increased sleep latency,
reduced sleep efﬁciency, decreased sleep duration, and altered
sleep EEG parameters (reduced slow wave activity; alterations in
spectral power in different brain wave bands) among participants.
Although these objective sleep parameters were altered following
caffeine intake, participants may not have actually experienced any
subjective effects on their sleep quality as reported in Landolt et al.
(1995a).Two studies examined the relationship between adenosine
deaminase (Mazzotti et al., 2011) and adenosine receptor (Retey
et al., 2007) polymorphisms and caffeine intake on sleep parame-
ters. In a study of 958 adults, Mazzotti et al. (2011) reported that
carriers of an adenosine deaminase polymorphism (A allele car-
riers) had lower sleep latency, higher sleep efﬁciency, a higher REM
sleep percentage, and fewer minutes awake following caffeine
consumption of at least 1 cup of a caffeine-containing beverage
(caffeine intake not otherwise identiﬁed) the day prior compared to
non-A allele carriers. These differences were not observed among
those who did not consume caffeine.
Retey et al. (2007) reported that caffeine consumption (400 mg)
was signiﬁcantly associated with subjectively reduced sleep quality
(sleep latency longer than 20 min, and frequent awakenings) in 12
caffeine-sensitive, but not in 10 caffeine-insensitive respondents
(based on questionnaire). A higher prevalence of the ADORA2A
c.1083C/C polymorphism was observed in the caffeine sensitive
group, while fewer sleep disturbances as well as less of an effect on
sleep EEG activity was observed among carriers of the ADORA2A
c.1083T allele.
3.3. Anxiety
Anxiety is deﬁned as an emotion characterized by feelings of
tension and worried thoughts. In the studies evaluated here, it is
generally assessed by standardized questionnaires (e.g., proﬁle of
mood states e POMS), or using a visual analog scale It is, therefore,
subjective, and does not constitute an adverse effect, except in the
case of medically diagnosed anxiety disorder.
A total of 57 studies (47 experimental, 10 observational) exam-
ined the potential relationship between caffeine intake and various
endpoints related to anxiety (e.g., anxiety test scales, tension, self-
reported jitteriness). These endpoints were studied primarily
among adult participants, with 4 observational and 3 experimental
studies of children. Drawing conclusions fromobservational studies
on these endpoints is problematic given that only associations can
be evaluated, not cause-and-effect. Moreover, it is difﬁcult to
distinguish between outcomes associated with caffeine intake per
se versus those relative to both an individual's personality and
preference for caffeinated products or higher caffeine intake. Some
individuals may in fact be consuming caffeine to self-medicate for
anxiety symptoms resulting from personal disinhibition (Trapp
et al., 2014). For example, the authors of two studies reported
higher mean anxiety scores among those who were “dependent”
on caffeine compared to those who were non-dependent, even
though the dependent groups consumed less caffeine (Bernstein
et al., 2002; Oberstar et al., 2002). In these studies, identiﬁcation
of “dependence” or personal disinhibition was based on DSM-IV
(Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.)
substance dependence criteria e meeting at least three of four
criteria (reported tolerance, endorsement of withdrawal symptoms
when stopping or cutting down consumption, persistent desire or
unsuccessful efforts to control use, and reported drinking caffeine
despite physical or psychological problems associated with caffeine
use).
Another important point to consider is the potential effect of
abstaining from caffeine during an experimental study that could
itself lead to an increase in anxiety symptoms due to withdrawal
symptoms experienced by regular or high caffeine users (Goldstein
et al., 1969; Rapoport et al., 1984; Rogers et al., 2003, 2010).
Among 8 experimental (Botella and Parra, 2003; Childs and de
Wit, 2006; Childs et al., 2008; Huppe and Janke, 2001; Lieberman
et al., 1987; Miller et al., 1998; Peacock et al., 2014; Richardson
et al., 1995) and 4 observational (Eaton and McLeod, 1984; Gold
et al., 2007; Oberstar et al., 2002; Trapp et al., 2014) studies that
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intake (<100 mg) and anxiety, the authors of one study reported an
effect associated with caffeine intake that was potentially related to
anxiety (Richardson et al., 1995). Richardson et al. (1995) reported a
signiﬁcant excess in jitteriness e an undesirable but not adverse
effect e among adults (49 “moderate” caffeine consumers and 18
non-consumers) that received 70 mg of caffeine compared to those
that received none. However, the authors noted that the increase in
jitteriness paralleled a decrease in hand-steadiness and could have
been related to an increase in muscle tremors rather than an in-
crease in anxiety. In a survey of 1062 young adults, Trapp et al.
(2014) reported a signiﬁcant association between energy drink
intake 250 mL/day (80 mg caffeine/day) and anxiety symptoms
in young adult males (mean age 20 ± 3), but not in females, while
anxiety symptoms were not signiﬁcantly increased among partic-
ipants of either sex who drank < 250 mL/day. The results of the
remaining studies indicated no effect e undesirable or otherwise e
of low levels of caffeine on measures of anxiety. Two of the studies
however did report lower anxiety scores following caffeine intakes
ranging from 50 to 100 mg (Hüppe and Janke, 2001; Peacock et al.,
2014).
Most of the studies involved an examination of the effects of
caffeine at doses ranging from 150 to about 500 mg. Increases in
self-reported symptoms of anxiety were reported in some in-
dividuals at dose levels as low as 150 mg (Alsene et al., 2003;
Botella and Parra, 2003; Childs et al., 2008; Goldstein et al., 1969).
Among the studies that examined the effects of caffeine at doses
ranging from 150 to 500 mg/day results were generally mixed.
Among studies where participants received caffeine doses as high
as 400e500 mg or more, some reported no signiﬁcant changes in
anxiety symptoms (Azcona et al., 1995; Bonnet and Arand, 2003;
Hughes and Boland, 1992), while several others did report a sig-
niﬁcant association (Attwood et al., 2007; Bruce et al., 1992; Brunye
et al., 2010; Childs et al., 2008; Kaplan et al., 1997; Nardi et al.,
2007a,b; Nardi et al., 2008; Rapoport et al., 1981, 1984). Among
three studies that examined the effects of caffeine at doses ranging
from 700 to 1200 mg in individuals whose normal caffeine con-
sumption was low (<100 mg/day) to moderate (<400 mg/day), all
reported a signiﬁcant increase in anxiety symptoms following
caffeine consumption (Bonnet and Arand, 2003; Motl and Dishman,
2004; Youngstedt et al., 1998).
Ten experimental studies included testing of salivary caffeine
levels in participants (Bernstein et al., 1994; Brice and Smith, 2002;
Bruce et al., 1992; Childs and de Wit, 2006; James and Gregg, 2004;
Lader et al., 1996; Rapoport et al., 1981, 1984; Rogers et al., 2010;
Smith et al., 2006). Among these studies, caffeine doses ranging
from 200 to 500 mg (roughly equivalent to 3e7 mg/kg bw) were
statistically signiﬁcantly associated with an increase in measures of
anxiety. Two studies reported no effect on anxiety following
ingestion of 2.5e5.25 mg/kg bw/day caffeine when administered in
a single dose, or recurrently for a period of 4 weeks (Bernstein et al.,
1994; James and Gregg, 2004). In addition, one study (Lieberman
et al., 1987) measured plasma caffeine 3-h after caffeine inges-
tion, and noted a clear relationship between caffeine dose
(32e256mg) and plasma concentration (about 0.8e4.5 mg/mL), but
no effect on anxiety or other mood state.
Certain factors appeared to modify the purported effects
caffeine had on various measures of anxiety. These included
caffeine habit, genetics, and pre-existing anxiety disorders. Anxiety
effects following caffeine intake were generally increased among
naïve caffeine users (low or no regular consumption) compared to
regular or high consumers of caffeine (Goldstein et al., 1969;
Rapoport et al., 1984; Rogers et al., 2010; Smith et al., 2006). In-
dividuals with pre-existing anxiety disorders (e.g., general anxiety
disorder, panic disorder) were at greater risk of experiencinganxiety symptoms following a single caffeine dose of 250mg (Bruce
et al., 1992), but no increase in panic attacks at that dose level
(Matthew andWilson, 1990) while an increase in panic attacks was
reported in panic disorder patients, but not in normal individuals or
individuals with other mental disorders given a single caffeine dose
of 480 mg (Nardi et al., 2007a,b; 2008).
Susceptibility to anxiogenic effects of caffeine is inﬂuenced by
adenosine receptor gene polymorphisms. Childs et al. (2008) found
carriers of two ADORA2A polymorphisms displayed increased
symptoms of anxiety after 150 mg caffeine, while non-carriers
showed effects only at 450 mg. Rogers et al. (2010) reported a
similar relation between ADORA2A polymorphism and anxiogenic
effect of caffeine, but also reported that tolerance to the anxiogenic
effect of caffeine was illustrated by the fact that carriers of the
“sensitive” polymorphism whose normal caffeine intake was me-
dium (128 ± 46 mg) or high (346 ± 129 mg) did not show an in-
crease in anxiety following caffeine dosing (100 mg þ 125 mg 90-
min later), while subjects whose normal caffeine intake was low
or zero did show increased anxiety when dosed in the same way.
Thus, tolerance to caffeine consumption occurs when habitual
users of caffeine e including genetically susceptible individuals e
become desensitized to its physiological effects such that additional
intake does not contribute to any further increase in these effects.
Among the four observational studies of children, the dose in-
formation reported in three of the studies was too imprecise to
draw any ﬁrm conclusions about speciﬁc dose-effects (Bernstein
et al., 2002; Ludden and Wolfson, 2010; Oberstar et al., 2002).
Among the three experimental studies of children (age 8 to 13) who
consumed caffeine doses ranging from 2.5 to 10 mg/kg bw (mean
body weight 37e39 kg), a signiﬁcant increase in anxiety symptoms
were reported only at doses of 10 mg/kg bw (Rapoport et al., 1981,
1984).
3.4. Aggression/risk-taking behavior
Aggression/risk-taking behavior was addressed in the studies
evaluated by several methods, including observation of subjects by
a researcher and identiﬁcation of behaviors thought to represent
aggression, collection of self-reported feelings of anger or aggres-
sive behavior, or participation in computer games designed to re-
cord responses believed by the study authors to be indicative of
aggressive or risk-taking behaviors.
A total of 15 studies (10 experimental, 5 observational) included
an evaluation of the potential relationship between caffeine intake
and various endpoints related to aggression and/or risk-taking
behavior (e.g., mood state, performance on gambling tasks,
behavior). These endpoints were studied primarily in adult pop-
ulations. There was only one study of children with a mean age of
14 years of age. As with anxiety-related endpoints, drawing con-
clusions from observational studies of these endpoints is prob-
lematic as only associations can be explored, not cause-and-effect.
Differentiating between outcomes associated with caffeine intake
per se versus outcomes relative to both an individual's personality
and propensity for risk-taking and preference for caffeinated
products is challenging. The primary strengths of the experimental
studies include the assessment of baseline behavior or risk-taking
propensity prior to the assessment of these measures during
speciﬁed sessions involving caffeine intake. This allows any po-
tential differences in risk-taking behavior or mood to be more
conﬁdently attributed to speciﬁc caffeine doses.
Among the ﬁve observational epidemiology studies, a variety of
caffeinated products were examined including energy drinks
(Miller, 2008; Spierer et al., 2014), coffee (Baethge et al., 2009), and
caffeinated beverages in general including soda, tea, or coffee
(Jones and Lejuez, 2005; Martin et al., 2008). These studies present
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tional studies does not allow one to determine a temporal rela-
tionship (i.e., whether consumption of energy drinks preceded an
individual's propensity for risk-taking behavior or vice versa). The
dose-information provided in the study of coffee drinkers and the
studies involving energy drinks were not precise enough to deter-
mine speciﬁc dose-related associations. Observational studies
involving the use of energy drinks often do not account for vari-
ables such as motivations for use, expectancies prior to use, per-
sonality, or genetics, which may be related to both the decision to
use them in the ﬁrst place and to engage in risk-taking behavior.
The results of the remaining two studies were mixed. Jones and
Lejuez (2005) reported no signiﬁcant difference in scores on a
risk-taking task between 30 high (mean: 423 mg/day, range:
241e1471 mg/day) and 30 low (mean: 14 mg/day, range:
0.41e24 mg/day) consumers of caffeine. Martin et al. (2008) re-
ported signiﬁcantly higher aggressive behavior scores among high
consumers of caffeine (4 drinks/day) compared to medium (2e3
drinks/day) or low (0e1 drinks/day) consumers in a study of 132
adolescents.
Three experimental studies examined the effects of low levels of
caffeine intake (<100 mg) on aggressive (Baer, 1987; Cherek et al.,
1983) or risk-taking behavior (Peacock et al., 2013). Cherek et al.
(1983) tested the effects of 0, 1, 2, or 4 mg/kg bw caffeine in 8
adult subjects using a test measuring aggression towards other
opponents in a game. Caffeine had a suppressive effect on aggres-
sive responding, which was statistically signiﬁcant at the highest
dose (4mg/kg bw). Peacock et al. (2013) reported signiﬁcantlymore
pumps in a balloon pumping exercise among 28 adult participants
who consumed roughly one energy drink (~3.57 ml/kg bw Red
Bull), suggesting a propensity for risk taking among this group. Baer
(1987) investigated the effects of a single, sugar-free cola on
classroom behavior (including aggressive behavior) on 6 kinder-
garten children, and noted no consistent effect.
Among ﬁve experimental studies that examined the effects of
moderate levels of caffeine ranging from about 150 to 400mg, most
did not ﬁnd a signiﬁcant effect on subjective feelings of anger
(Arciero et al., 1998; Arciero and Ormsbee, 2009) or aggressive
behavior (Cherek et al., 1983, 1984). Similar to the results reported
by Cherek et al. (1983), discussed previously, Cherek et al. (1984)
reported that consumption of 500 ml of regular instant coffee
compared to decaffeinated coffee produced decreases in aggressive
responses in 8 adults. Arciero et al. (1998) and Arciero and Ormsbee
(2009) reported no signiﬁcant increase in feelings of anger among
men andwomen that consumed 5mg/kg bw caffeine. Anger tended
to decrease following caffeine consumption in 10 older and 10
younger women in the 2009 study, and tended to decrease in 10
older, but not 10 younger men, in the 1998 study. Attwood et al.
(2007) reported a signiﬁcantly increased rating of “tense negative
mood” (including: tense, jittery, angry, dejected) among those who
consumed 400 mg caffeine compared to placebo. More negative
effects were observed among 24 moderate consumers (<200 mg
caffeine/day) compared to 21 heavy consumers (>200 mg caffeine/
day), which the authors suggested may have been due to the
development of a tolerance for the aversive effects of caffeine by
the high consumers.
Three experimental studies examined the effects of caffeine
intake of 600 mg or more on risk taking behavior following sleep
deprivation. Killgore et al. (2007, 2008, 2011) examined the effect of
caffeine consumption on risk-taking behavior through the use of
gambling tasks or application of a self-report questionnaire indi-
cating propensity for risk-taking. Caffeine intake had no effect or
led to a reduction in risk-taking behavior. After 44 h of sleep
deprivation, Killgore et al. (2008) reported declines in some mea-
sures of risk-taking that were unaffected by caffeine (600 mg) in 54healthy adults (29 M, 25 F). Killgore et al. (2007) reported similar
results following 75 h of sleep deprivation and intake of 800 mg of
caffeine in 26 healthy adults (21 M, 5 F). After 75 h of sleep
deprivation, Killgore et al. (2011) reported increased risk-taking in
25 adults (21 M, 4 F) that was counteracted by 800 mg caffeine
(200 mg every 2 h during the last night prior to testing).
While more than a dozen studies have attempted to examine
whether there is a relationship between caffeine consumption and
risk-taking or aggressive behavior, no clear pattern emerges
(Mahoney et al., 2012). Experimental studies that examined the
effects of high doses of caffeine reported either no effect, or a
reduction in risk-taking behavior.
3.5. Tolerance/withdrawal
Tolerance or acclimation to some of the acute effect of caffeine
develops with repeated and regular intake. For example, while
caffeine may result in a slight increase in the blood pressure of
naive individuals, regular caffeine consumers rapidly develop
tolerance and no longer respond to caffeine intake with an increase
in blood pressure (Robertson et al., 1981).
Tolerance also develops to increases in tension, anxiety, and
jitteriness associated with caffeine administration (Morelli and
Simola, 2011). Thus, tolerance to caffeine consumption may be
characterized as a desensitization to effects from caffeine among
habitual users e including genetically susceptible individuals e
such that additional moderate intake does not contribute to any
further increase in physiological effects. Very high doses are
required to elicit adverse effects.
Abrupt discontinuation of caffeine consumption results in a
mild withdrawal syndrome, characterized by headache, fatigue,
drowsiness, irritability, depressed mood, and anxiety, starting after
12e24 h of abstinence, and peaking 20e48 h later. Symptoms of
caffeine withdrawal vary considerably between different in-
dividuals. The withdrawal syndrome is usually not harmful, and is
self-limiting (Morelli and Simola, 2011).
4. Summary and conclusions
This investigation has conﬁrmed what has long been known,
that caffeine, even at acute doses of 100 mg or less in an adult can
produce physiological CNS effects. The most sensitive effect seems
to be caffeine's beneﬁcial effect on alertness. Caffeine can also have
subtle effects on sleep parameters at similar or slightly higher doses
when consumed close to the normal sleep time. These two effects
likely both represent manifestations of caffeine's interaction with
the adenosine receptor, counteracting adenosine's inhibitory ac-
tions, and affecting its role in sleep-wake regulation. This effect of
caffeine is both well known to consumers and self-limiting, i.e.,
self-titration, leading many consumers to refrain from consuming
caffeinated beverages late in the day. The effect is also transient and
completely reversiblewhen consumption stops, and does not result
in any adverse health effects.
Studies examining effects on anxiety showed mixed results at
doses in the range of 150e500 mg (in adults), but clearer effects at
doses of 700e1200 mg (10 mg/kg bw or more). In the few studies
that examined effects in children, similar results were seen, with a
clear increase in anxiety symptoms at doses above 10 mg/kg bw,
similar to that for adults. There is some evidence of possible
increased effects on subjective anxiety in carriers of certain aden-
osine receptor polymorphisms (Childs et al., 2008), with carriers of
some polymorphisms showing signs of increased anxiety with
caffeine doses of 150 mg, while non-carriers showed effects only at
450 mg, and carriers of some other polymorphisms showed
reduced anxiety following caffeine ingestion. Differences noted on
Table 1
Summary of key ﬁndings on CNS effects of caffeine.
Intake Sleep Anxiety Aggression/risk-taking
<100 mg One experimental study reported
“virtually no effect on sleep patterns,”
among 18 young adult men when
administered 30-min before retiring
(Karacan et al., 1976).
In one cross-sectional study of 11,267
children, “sleeping problems” were
reported in 10e12 year old boys, but
not girls who consumed <1 caffeinated
drink/day (time of consumption not
recorded) (Kristjansson et al., 2014).
Among 8 experimental and 4 observational studies
(Botella and Parra, 2003; Childs and de Wit, 2006;
Childs et al., 2008; Huppe and Janke, 2001;
Lieberman et al., 1987; Miller et al., 1998; Peacock
et al., 2014; Richardson et al., 1995; Eaton and
McLeod, 1984; Gold et al., 2007; Oberstar et al.,
2002; Trapp et al., 2014), the authors of just a single
study (Richardson et al., 1995) reported a signiﬁcant
excess in “jitteriness” e an undesirable but not
adverse effect e among adults that received 70 mg
of caffeine compared to those that received none.
The results of the remaining studies indicated no
adverse effect of low levels of caffeine on measures
of anxiety, while two of the studies reported lower
anxiety scores following caffeine intakes (Hüppe
and Janke, 2001; Peacock et al., 2014).
Cherek et al. (1983) tested the effects of 0, 1, 2, or
4 mg/kg bw caffeine in 8 subjects using a test
measuring aggression towards other opponents in a
game. Caffeine had a suppressive effect on
aggressive responding, which was statistically
signiﬁcant at the highest dose (4 mg/kg bw).
Peacock et al. (2013) reported signiﬁcantly more
pumps in a balloon pumping exercise e a surrogate
indicator for risk-taking behavior e among 28
participants that consumed roughly one energy
drink (3.57 ml/kg Red Bull), suggesting a propensity
for risk-taking among this group.
Baer (1987) investigated the effects of a single,
sugar-free cola on classroom behavior (including
aggressive behavior) in 6 kindergarten children, and
noted no consistent effect.
100e600 mg Subtle effects on sleep parameters were
observed at doses as low as 100 mg
when given immediately prior to
retiring (Landolt et al., 1995a), with
clear dose-related effects at higher
doses. Some studies suggest a lack of
effect on sleep when caffeine is given 6
e16 h before sleep (Snel, 1993; Bonnet
and Arand, 1992; Pontifex et al., 2010).
Similar results were observed among 11
studies where salivary caffeine levels
were also measured, including
increased sleep latency, reduced sleep
efﬁciency, decreased sleep duration,
and altered electroencephalography
(EEG) parameters (e.g., reduced slow
wave activity; alterations in spectral
power in different brain wave bands)
(Carrier et al., 2007; Carrier et al. 2009;
Drapeau et al., 2006; Hale et al., 1995;
James, 1998; Lader et al., 1996; Landolt
et al., 1995a; Landolt et al. 1995b;
Paterson et al., 2007; Retey et al., 2007;
Sicard et al., 1996).
One study in children (grades 6e10)
who drank 1 coffee or soda per day
(time of consumption not recorded)
were signiﬁcantly more likely to report
difﬁculty sleeping compared to children
with very low intake (<1/week), with
no effects in the low intake group
(Orbeta et al., 2006).
Carriers of the adenosine deaminase
polymorphism (A allele carriers) had
lower sleep latency, higher sleep
efﬁciency, a higher rapid eyemovement
(REM) sleep percentage, and fewer
minutes awake following caffeine
consumption of at least 1 cup of a
caffeine-containing beverage the day
prior (time not recorded) compared to
non-A allele carriers (Mazzotti et al.,
2011).
Intake of caffeine was signiﬁcantly
associated with subjectively reduced
sleep quality in caffeine-sensitive but
not in caffeine-insensitive participants
(based on questionnaire). A higher
prevalence of the ADORA2A c.1083C/C
polymorphism was observed in the
caffeine-sensitive group (Retey et al.,
2007),
Maternal consumption of 300 mg/day
caffeine during the 1st, 2nd, or 3rd
trimester, during the whole pregnancy,
or at 3 months postpartum was not
signiﬁcantly associated with >3 night-
Increases in self-reported symptoms of anxiety
were reported in some individuals at dose levels as
low as 150 mg (Alsene et al., 2003; Botella and
Parra, 2003; Childs et al., 2008; Goldstein et al.,
1969). Results were generally mixed among studies
that examined the effects of caffeine at doses
ranging from 150 to 500mg. Some authors reported
no signiﬁcant changes in anxiety symptoms
following doses as high as 400e500 mg (Azcona
et al., 1995; Bonnet and Arand, 2003; Hughes and
Boland, 1992), while several others did (Attwood
et al., 2007; Bruce et al., 1992; Brunye et al., 2010;
Childs et al., 2008; Kaplan et al., 1997; Nardi et al.,
2007a,b; Nardi et al., 2008; Rapoport et al., 1981,
1984).
Mixed results were similarly reported among nine
experimental studies that included testing of
salivary caffeine levels (Bernstein et al., 1994; Brice
and Smith, 2002; Bruce et al., 1992; Childs and de
Wit, 2006; James and Gregg, 2004; Lader et al.,
1996; Rapoport et al., 1981; Rapoport et al. 1984;
Rogers et al., 2010).
Individuals with pre-existing anxiety disorders (e.g.,
general anxiety disorder, panic disorder) were at
greater risk of experiencing anxiety symptoms
following caffeine intake of 250 mg (Bruce et al.,
1992) or panic attacks at 480 mg (Nardi et al.,
2007a,b; 2008).
Carriers of two ADORA2A polymorphisms displayed
increased symptoms of anxiety after 150 mg
caffeine, while non-carriers showed effects only at
450 mg (Childs et al., 2008). Another study of
ADORA2A polymorphisms reported similar results;
however a tolerance to the anxiogenic effects of
caffeine were observed among medium and high
regular consumers of caffeine (Rogers et al., 2010).
Among the three experimental studies of children
(age 8 to 13) who consumed caffeine doses ranging
from 2.5 to 10 mg/kg bw (mean body weight 37
e39 kg), a signiﬁcant increase in anxiety symptoms
were reported only at doses of 10 mg/kg (Bernstein
et al., 1994; Rappaport et al., 1981, 1984).
Among ﬁve experimental studies that examined the
effects of moderate levels of caffeine ranging from
about 150 to 400 mg, most did not ﬁnd a signiﬁcant
effect on subjective feelings of anger or aggressive
behavior (Arciero et al., 1998; Arciero and Ormsbee,
2009; Attwood et al., 2007; Cherek et al., 1983,
1984).
Decreases in aggressive responses were observed in
two studies following higher caffeine intakes
(Cherek et al., 1983, 1984). Anger tended to
decrease following caffeine consumption in older
and younger women, and tended to decrease in
older men, but not younger, in two other studies,
respectively (Arciero et al., 1998; Arciero and
Ormsbee, 2009).
One study reported a signiﬁcantly increased rating
of “tense negative mood” (including: tense, jittery,
angry, dejected) among those who consumed
400 mg caffeine per day compared to placebo
(Attwood et al., 2007). These effects were more
commonly observed among 24 “moderate”
consumers (<200 mg/day) compared to 21 “heavy”
consumers (>200 mg/day). The authors
hypothesized that a tolerance for the undesirable
aversive effects of caffeine was developed by the
heavy consumers.
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Intake Sleep Anxiety Aggression/risk-taking
time wakings per night among infants
at 3 months of age (Santos et al., 2012).
>600 mg Among six studies in which caffeine
was consumed close to retiring, the
authors reported reductions in total
sleep time and sleep quality, and
increased sleep latency and number of
awakenings (Bonnet and Arand, 1992,
1996; LaJambe et al., 2005; Sanchez-
Ortuno et al., 2005; Shilo et al., 2002;
Youngstedt et al., 2000).
In one study where participants
received 1200 mg/day caffeine (divided
in three doses, including one close to
retiring) for seven days, a variety of
sleep parameters were negatively
affected including total sleep time,
sleep latency, wake time, sleep
efﬁciency, number of wakes, and
arousal (Bonnet and Arand, 1992).
Signiﬁcant differences in effects
observed on day one of the trial
disappeared for many of these
parameters after the ﬁrst day of caffeine
intake (total sleep time, sleep latency,
wake time, sleep efﬁciency, number of
wakes), suggesting evidence of
acclimation and a reversal of effects.
Among three studies that examined the effects of
caffeine at doses ranging from 700 to 1200 mg in
individuals whose normal caffeine consumption
was low (<100 mg/day) to moderate (<400 mg/
day), all reported a signiﬁcant increase in anxiety
symptoms following caffeine consumption (Bonnet
and Arand, 2003; Motl and Dishman, 2004;
Youngstedt et al., 1998).
Among three experimental studies that examined
the effects of caffeine intake of 600e800 mg on risk
taking behavior following sleep deprivation,
caffeine intake had either no effect or, in fact, led to
a reduction in risk-taking behavior (Kilgore et al.,
2007, 2008, 2011).
Notes The strengths of the literature available
for this review include the
experimental study design for the
majority of the studies, speciﬁc dose
information, as well as objective
measures of sleep quality.
Although certain objective sleep
parameters were altered following
caffeine intake in some (but not all) of
these studies, individuals may not
actually experience any subjective
effects on sleep quality as was reported
in at least one study.
The results reported in these studies do
not suggest any serious or long-term
harm to health. Any potential
undesirable (but not adverse) effects on
sleep quality experienced in daily life
would likely lead one to adjust their
caffeine intake so as to avoid those
effects in the future, i.e., self-titrate.
Caffeine habit, genetics, and pre-existing anxiety
disorders appeared to modify the effect that
caffeine had on various measures of anxiety. Effects
were generally increased among naïve caffeine
users (low or no regular consumption).
The strengths of the literature available for this
review include the experimental study design for
the majority of the studies with speciﬁc dose
information.
Drawing conclusions from observational studies on
anxiety endpoints is problematic given that only
associations can be evaluated, not cause-and-effect.
Moreover, it is difﬁcult to distinguish between
outcomes associated with caffeine intake per se
versus those relative to both an individual's
personality or motivations and preference for
caffeinated products and/or higher caffeine intake.
The strengths of the literature available for this
review include the experimental study design for
the majority of the studies with speciﬁc dose
information. These studies also include the
assessment of baseline behavior or risk-taking
propensity prior to the assessment of these
measures during speciﬁed sessions involving
caffeine intake. This allows any potential differences
in risk-taking behavior or mood to be more
conﬁdently attributed to speciﬁc caffeine doses.
Drawing conclusions from observational studies of
these endpoints is problematic given that
observational studies can only evaluate
associations, not cause-and-effect. Moreover, it is
difﬁcult to distinguish between outcomes
associated with caffeine intake per se versus those
relative to both an individual's personality and
propensity for risk-taking, and preference for
caffeinated products.
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adverse health effects. One phenomenon that may rise to the level
of a true adverse effect is the apparent ability of a fairly high acute
dose of caffeine (480 mg) to elicit panic attacks in some individuals
with a medically diagnosed panic disorder (Nardi et al., 2007a, b,
2008; 2009), though Mathew and Wilson (1990) reported no in-
crease in anxiety or panic attacks in subjects diagnosed with panic
disorder or general anxiety disorder when given a single 250 mg
dose of caffeine, suggesting a fairly high threshold for effects even
in this group e more than 2½ cups of brewed coffee, or more than
40 ounces of regular cola-type soft drink.
Studies designed to address the existence of a relationship be-
tween caffeine consumption and aggression or risk-taking do not
support such a relationship. Cross-sectional observational studies
can only evaluate associations and suffer from an inability to
examine temporal relationships and differentiate cause-and-effect.
Moreover, experimental studies do not show a consistent pattern of
results Table 1.Acknowledgment
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